Oneview Healthcare Chess Depository Interests repr 1 (ONE) AI Stock Analysis

• Market Cap: AU$207.15M
• Dividend Yield: N/A
• Average Volume (3M): 344.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 21.56%
• EPS Growth: -24.08%
• Country: AU
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 767,229,900
• 10 Day Avg. Volume: 303,620
• 30 Day Avg. Volume: 344,030
• PEG Ratio: 0.76
• Price to Book (P/B): 47.09
• Price to Sales (P/S): 14.39
• P/FCF Ratio: -20.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.50
• Price Target Upside: 92.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.01
• Revenue Forecast (FY): AU$15.75M

• Rating: 47 Neutral
• Price Target: AU$0.23 ▼(-11.15% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by weak financial performance—large ongoing losses and sustained negative cash flow—alongside bearish technical signals (below key moving averages with negative MACD). Offsetting factors include a relatively manageable leverage profile and a more positive earnings-call outlook citing continued growth targets and measurable cost-efficiency improvements, though execution and cash runway remain key risks.

Positive Factors

Revenue Growth & ARR Momentum

Sustained revenue growth (21% reported, >25% constant currency) and 7% ARR expansion indicate improving product-market fit and recurring revenue scale. Over 2–6 months this underpins more predictable top-line growth, supports operating leverage potential and reduces sole reliance on one-off revenues.

Baxter GPO Partnership & Market Access

Inclusion in a major Baxter GPO materially expands structural access to US hospital procurement channels and creates a large, persistent opportunity set (156+ qualified leads). This partnership improves distribution scale and long-term customer reach, lowering go-to-market friction for enterprise deployments.

OpEx Reduction & Cost Discipline

Realized H2 OpEx reductions (9% half-on-half; >€1.4m annualized) demonstrate durable cost discipline and a structural move to lower cash burn. Carried into 2026, these savings improve runway and, combined with product productivity gains, increase the chance of reaching sustainable profitability without proportionally higher revenues.

Negative Factors

Persistent Negative Cash Flow

Consistent negative operating and free cash flow indicates the business consumes cash to fund operations. Over a multi-month horizon this raises dependence on external financing, heightens dilution or refinancing risk, and constrains the company’s ability to invest in sales or product expansion without improving cash conversion.

Ongoing Operating Losses

An €8.1m EBITDA loss, despite narrowing, signals structural operating deficits relative to current scale. Continued losses depress returns, pressure equity, and mean management must sustain cost cuts and growth simultaneously. Absent sustained margin expansion, the firm risks repeating cash shortfalls within a few quarters.

Long Sales Cycles & Pipeline Conversion Risk

Enterprise sales cycles of 18–24 months create durable timing risk: booked pipeline and GPO inclusion may take many quarters to convert. This slows revenue realization, extends breakeven timelines, and increases the need for capital to bridge sales conversion periods, limiting near-term financial flexibility.

Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model

Company Description

Oneview Healthcare Chess Depository Interests repr 1 (ONE) is a healthcare technology company that focuses on providing innovative digital solutions to enhance patient and operational outcomes in the healthcare sector. The company primarily offers a digital patient engagement platform that streamlines communication between healthcare providers and patients, facilitates data sharing, and improves overall patient experience. Oneview Healthcare operates within the broader healthcare technology industry, catering to hospitals, clinics, and other healthcare organizations seeking to modernize their patient care processes.

How the Company Makes Money

Oneview Healthcare generates revenue through a subscription-based model, where healthcare providers pay for access to its digital platform and services. Key revenue streams include licensing fees for the software, ongoing subscription fees, and additional charges for premium features or services such as training and support. The company may also partner with healthcare institutions and technology vendors to integrate its solutions, which can lead to additional revenue opportunities through collaborative projects and shared initiatives aimed at enhancing patient care and operational efficiency.

Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview

Summary

Revenue is growing (FY25 up ~21% YoY), but financial quality remains weak due to very large ongoing net losses (FY25 net loss ~-$12.5M on ~$11.9M revenue) and persistent negative operating/free cash flow (FY25 OCF about -$8.3M; FCF about -$8.4M). Leverage appears manageable in reported periods (debt-to-equity ~0.09–0.10), but continued losses and cash burn keep balance sheet pressure elevated.

Income Statement

Revenue has grown steadily in recent years (2025 up ~21% vs. 2024; 2024 and 2023 low-single-digit growth), and gross profit remains solid in dollar terms. However, the company continues to post very large operating and net losses each year (2025 net loss ~-$12.5M on ~$11.9M revenue), implying operating costs remain structurally high relative to its current scale. Overall, the top line trend is improving, but profitability and operating leverage remain the clear weakness.

Balance Sheet

Leverage looks manageable in the years where it’s provided (debt-to-equity ~0.09 in 2024 and ~0.10 in 2023), which reduces near-term balance sheet risk versus highly levered peers. That said, equity has been volatile (notably lower in 2025 vs. 2024) and returns on equity are deeply negative due to ongoing losses, signaling continued balance sheet pressure if losses persist.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are negative across all periods shown, including 2025 operating cash flow of about -$8.3M and free cash flow of about -$8.4M. While free cash flow improved versus 2024, the business is still consuming cash rather than funding itself internally, increasing dependence on external financing until profitability and cash burn improve.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.93M	9.89M	9.40M	8.92M	9.73M
Gross Profit	7.12M	6.67M	6.16M	5.35M	5.31M
EBITDA	-10.48M	-11.26M	-7.88M	-12.09M	-8.01M
Net Income	-12.51M	-10.84M	-8.93M	-10.87M	-8.19M
Balance Sheet
Total Assets	15.49M	25.96M	21.92M	12.75M	21.09M
Cash, Cash Equivalents and Short-Term Investments	4.60M	13.83M	11.55M	6.41M	15.18M
Total Debt	1.99M	1.15M	935.32K	543.01K	1.20M
Total Liabilities	11.84M	12.71M	12.78M	10.50M	11.19M
Stockholders Equity	3.65M	13.25M	9.14M	2.26M	9.90M
Cash Flow
Free Cash Flow	-8.38M	-10.52M	-7.79M	-10.24M	-4.09M
Operating Cash Flow	-8.32M	-10.47M	-7.26M	-10.20M	-4.03M
Investing Cash Flow	-116.31K	-459.78K	-521.38K	-44.52K	-65.26K
Financing Cash Flow	-294.26K	13.14M	13.04M	-100.11K	12.22M

Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.34, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 22.00 is Positive, neither overbought nor oversold. The STOCH value of 1.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ONE.

Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	67 Neutral	AU$141.01M	36.21	1.89%	―	10.06%	―
CGS	66 Neutral	AU$392.86M	23.37	22.84%	0.88%	21.47%	89.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
M7T	48 Neutral	AU$78.73M	-7.86	-12.35%	―	15.99%	22.05%
ONE	47 Neutral	AU$207.15M	-9.41	―	―	21.56%	-24.08%
PCK	45 Neutral	AU$35.53M	-3.57	-8647.54%	―	25.98%	22.10%
BMT	44 Neutral	AU$46.50M	-8.04	-13.83%	―	3.61%	-17.03%

Oneview Healthcare Chess Depository Interests repr 1 Corporate Events

Oneview Healthcare Issues 620,000 Restricted Share Units Under Employee Incentive Plan

Oneview Healthcare plc has notified the market of the issue of 620,000 restricted share units under its employee incentive scheme, designated as unquoted equity securities on the ASX. The new instruments, which are subject to transfer restrictions until a specified expiry, reflect the company’s ongoing use of equity-based compensation to retain and motivate staff, potentially aligning employee interests more closely with long-term shareholder value.

The restricted share units, recorded under the ASX security code ONEAF, were issued with an effective date of 17 December 2025, with the formal announcement lodged on 23 February 2026. While the securities will not be quoted on the ASX until restrictions lapse, their issuance modestly increases Oneview’s pool of incentive equity and may have a small dilutive effect over time if converted into fully tradable shares.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Sets Date for FY25 Results and Investor Call

Oneview Healthcare PLC has scheduled the release of its full-year results for the financial year ended 31 December 2025 on 12 February 2026, and will host a conference call for investors and analysts on the same day at 8:00am AEDT, led by CEO James Fitter and CFO Darragh Lyons. The announcement sets expectations for upcoming financial disclosures and provides stakeholders with a formal forum to engage with management on the company’s performance and strategic direction.

The most recent analyst rating on (AU:ONE) stock is a Sell with a A$0.29 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Narrows Cash Outflows and Gains Strategic Access to Major US Health System

Oneview Healthcare reported a cash balance of €4.6 million at 31 December 2025 and a reduced net operating cash outflow of €1.4 million for the quarter, reflecting higher customer receipts, lower product manufacturing and operating costs, and reduced marketing spend compared with the prior year period. Operationally, the company sustained strong commercial momentum by securing a new five-year contract with Peterson Health in Texas, expanding deployments to nearly 14,900 live endpoints, progressing major implementations at Inova Health and other U.S. hospitals, and achieving a key milestone in its partnership with Baxter, which has now added Oneview’s products to a national care communication purchasing agreement for one of the ten largest U.S. health systems, potentially opening access to more than 85 hospitals and 15,000 beds, although future orders are not guaranteed.

The most recent analyst rating on (AU:ONE) stock is a Sell with a A$0.29 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Director’s Interest Update Reflects Strategic Confidence

Oneview Healthcare PLC announced a change in the director’s interest as Darragh Lyons acquired 3,000,000 Chess Depository Interests (CDIs) upon the vesting of Restricted Share Units (RSUs). This change reflects the company’s ongoing commitment to aligning executive interests with shareholder value, as approved by shareholders at the recent AGM. The acquisition of these CDIs suggests confidence in the company’s strategic direction and potential growth, which may positively impact stakeholder perceptions and market positioning.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Announces Director’s Interest Change

Oneview Healthcare PLC announced a change in the director’s interest, specifically regarding Barbara Nelson’s holdings. The change involved the acquisition of 327,868 Chess Depository Interests (CDIs) upon the vesting of Restricted Share Units (RSUs) under the company’s NED & Consultant RSU Plan, as approved by shareholders. This adjustment reflects the company’s ongoing efforts to align director incentives with shareholder interests, potentially impacting the company’s governance and stakeholder confidence.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Appoints New Director with No Initial Securities Interests

Oneview Healthcare PLC has announced the appointment of Michael Dowling as a director, effective from December 2, 2025. The initial director’s interest notice reveals that Mr. Dowling currently holds no securities or contracts related to the company, indicating a fresh start in his role without prior financial entanglements.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Issues Restricted Share Units to Employees

Oneview Healthcare PLC announced the issuance of 3,983,604 restricted share units under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize and retain key personnel, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare PLC Updates Constitution to Support Strategic Growth

Oneview Healthcare PLC has amended its constitution to include all special resolutions passed up to December 2025, reflecting its strategic focus on expanding its business operations and enhancing its property value. This move could potentially strengthen its market position and offer new opportunities for collaboration and growth within its industry.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Reports Transformative Growth and Innovation in 2025

Oneview Healthcare has experienced significant growth in 2025, marked by an increase in customer base and product innovation. The company maintained a strong financial position with disciplined cost control and a healthy cash reserve. Notable achievements include the addition of new clients such as Willis-Knighton Health System and White Plains Hospital, and the expansion of existing client partnerships, which contributed to a 20% growth in annual recurring revenue. The launch of Ovie, an AI-powered care assistant, highlights Oneview’s commitment to innovation, aiming to improve nurse efficiency and patient empowerment. The partnership with Baxter has also bolstered Oneview’s market presence, leading to a record sales pipeline.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Plc Reports Successful AGM Outcomes

Oneview Healthcare Plc held its Annual General Meeting on December 1, 2025, in Dublin, where all resolutions were passed, including the reappointment of directors and the approval of remuneration and stock awards. The meeting’s outcomes demonstrate strong shareholder support and are expected to positively impact the company’s governance and strategic initiatives.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.